Actively Recruiting

Age: 15Years - 80Years
All Genders
NCT05584722

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Led by Vanderbilt University Medical Center · Updated on 2026-03-10

150

Participants Needed

1

Research Sites

199 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD

CONDITIONS

Official Title

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Who Can Participate

Age: 15Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children and adults aged 15 to 80 years
  • Diagnosed with idiopathic or heritable pulmonary arterial hypertension (PAH) based on standard criteria
  • Unaffected mutation carriers: healthy individuals with a known BMPR2 gene mutation and normal pulmonary pressure and right ventricular function on echocardiogram
  • Healthy controls without cardiopulmonary disease
  • WHO functional class I to III
  • Stable PAH-specific medication regimen for at least three months before enrollment, allowing only a single diuretic adjustment or IV prostacyclin adjustments for side effects
Not Eligible

You will not qualify if you...

  • Unable to perform normal activities due to wheelchair, bed bound status, use of cane/walker, or activity-limiting conditions like angina or osteoarthritis
  • Pregnancy
  • PAH caused by other known etiologies besides idiopathic or heritable
  • Functional class IV heart failure
  • More than two diuretic adjustments within the three months prior to enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

Loading map...

Research Team

K

Kelly Burke, RN

CONTACT

A

Alisha Lindsey, RT

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here